Acute rejection characteristics from a prospective, randomized, double-blind, placebo-controlled multicenter trial of early corticosteroid withdrawal

Transplantation

Volumn 95, Issue 4, 2013, Pages 573-579

  Osama Gaber, A ^a,b   Moore, Linda W ^a   Alloway, Rita R ^c   Steve Woodle, E ^c   Pirsch, John ^d   Shihab, Fuad ^e   Henning, Alice ^f   Fitzsimmons, William ^g   Holman, John ^g   Reisfield, Robin ^g   Roy First, M ^g  

^a HOUSTON METHODIST HOSPITAL   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c UNIVERSITY OF CINCINNATI   (United States)

^d UNIVERSITY OF WISCONSIN MADISON   (United States)

^e UNIVERSITY OF UTAH   (United States)

^f EMMES CORPORATION   (United States)

^g ASTELLAS PHARMA GLOBAL DEVELOPMENT   (United States)

Author keywords

Corticosteroids; Kidney transplantation; Prednisone; Randomized controlled trial; Rejection

Indexed keywords

BASILIXIMAB; CORTICOSTEROID; DACLIZUMAB; INTERLEUKIN 2 RECEPTOR ANTIBODY; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; PREDNISOLONE; TACROLIMUS; THYMOCYTE ANTIBODY;

ACUTE GRAFT REJECTION; AGE; ARTICLE; BIOPSY; CADAVER KIDNEY; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG WITHDRAWAL; GRAFT FAILURE; HAZARD RATIO; HLA SYSTEM; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; LIVING DONOR; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PRIORITY JOURNAL; RACE DIFFERENCE; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK FACTOR; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT WITHDRAWAL;

ACUTE DISEASE; ADRENAL CORTEX HORMONES; AFRICAN AMERICANS; AGE FACTORS; ANTILYMPHOCYTE SERUM; BIOPSY; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; GRAFT REJECTION; GRAFT SURVIVAL; HISTOCOMPATIBILITY; HLA ANTIGENS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MULTIVARIATE ANALYSIS; MYCOPHENOLIC ACID; ODDS RATIO; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK FACTORS; TACROLIMUS; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 84874592113     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3182777efb     Document Type: Article

References (12)

1. Vanrenterghem Y, Lebranchu Y, Hene R, et al. Double-blind comparison of two corticosteroid regimens plus mycophenolate mofetil and cyclosporine for prevention of acute renal allograft rejection. Transplantation 2000; 70: 1352.
2. Vanrenterghem Y, Van Hooff JP, Squifflet J-P, et al. Minimization of immunosuppressive therapy after renal transplantation: results of a randomized controlled trial. Am J Transplant 2005; 5: 87.
3. Woodle ES, First MR, Pirsch J, et al. A prospective, randomized, double-blind, placebo-controlled multicenter trial comparing early (7 day) corticosteroid cessation versus long-term, low-dose corticosteroid therapy. Ann Surg 2008; 248: 564.
4. Knight SR, Morris PJ. Steroid avoidance or withdrawal after renal transplantation increases the risk of acute rejection but decreases cardiovascular risk. A meta-analysis. Transplantation 2010; 89: 1.
5. Gloor JM, Cohen AJ, Lager DJ, et al. Subclinical rejection in tacrolimustreated renal transplant recipients. Transplantation 2002; 73: 1965.
6. Gaber LW. Borderline changes in the Banff schema: rejection or no rejection? Transplant Proc 2004; 36: 755.
7. Meehan SM, Siegel CT, Aronson AJ, et al. The relationship of untreated borderline infiltrates by the Banff criteria to acute rejection in renal allograft biopsies. J Am Soc Nephrol 1999; 10: 1806.
8. Vereerstraeten P, Abramowicz D, de Pauw L, et al. Absence of deleterious effect on long-term kidney graft survival of rejection episodes with complete functional recovery. Transplantation 1997; 63: 1739.
9. Everly M, Everly J, Arrend L, et al. Reducing de novo donor-specific antibody levels during acute rejection diminishes renal allograft loss. Am J Transplant 2009; 9: 1063.
10. Devos JM, Gaber AO, Knight RJ, et al. Donor-specific HLA-DQ antibodies may contribute to poor graft outcome after renal transplantation. Kidney Int 2012; 82: 598.
11. Solez K, Benediktsson H, Cavallo T, et al. Report of the Third Banff Conference on Allograft Pathology (July 20Y24, 1995) on classification and lesion scoring in renal allograft pathology. Transplant Proc 1996; 28: 441.
12. Racusen LC, Solez K, Colvin RB, et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999; 55: 713.